Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Largely Avoids Partisan Bloodbath At US Pricing Hearing

Executive Summary

Democrats spent most of their time complaining about Senate Republicans' closed-door process for developing healthcare legislation, leaving little time for the expert witnesses to weigh in on drug pricing.

You may also be interested in...



Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says

US FDA commissioner tells House committee that culture changes – and label changes – are among the actions the agency is pursuing to address the opioid crisis.

Drug Pricing Legislation Appears Nowhere In Sight Following Senate Hearing

Senators and witnesses rehashed years-old arguments and found little common ground on which elements of drug pricing to address.

Drug Pricing Hearing In Senate Postponed, Handing Innovators Another Victory

First hearing in Sen. Alexander's committee was dominated by Democrat complaints about Obamacare repeal; now that there's an actual bill to criticize, the next one might have been even worse, but regardless of the reason, the postponement means innovator prices get to stay out of the spotlight once again.

Related Content

Topics

UsernamePublicRestriction

Register

RS009715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel